10-QPeriod: Q3 FY2016

THERMO FISHER SCIENTIFIC INC. Quarterly Report for Q3 Ended Oct 1, 2016

Filed November 4, 2016For Securities:TMO

Summary

Thermo Fisher Scientific Inc. (TMO) reported its third-quarter 2016 financial results, demonstrating continued revenue growth driven by both organic expansion and strategic acquisitions. Total revenues increased to $4.49 billion, up 9% year-over-year, primarily fueled by strong performance in the Life Sciences Solutions and Analytical Instruments segments. The company successfully integrated major acquisitions like FEI Company and Affymetrix, which significantly contributed to the top-line growth. Despite increased operating expenses related to these acquisitions and ongoing strategic investments, Thermo Fisher maintained a solid operating income margin. Financially, the company's balance sheet reflects substantial growth in assets, particularly in goodwill and acquisition-related intangible assets, a direct result of its aggressive acquisition strategy. The company also managed its debt effectively, issuing new debt to fund acquisitions and managing its existing obligations. Cash flow from operations remained robust, providing ample liquidity to support ongoing investments and debt servicing. Investors should note the company's continued focus on strategic growth through acquisitions, alongside operational efficiencies, positioning it for sustained long-term value creation.

Key Highlights

  • 1Total revenues for the third quarter of 2016 reached $4.49 billion, a 9% increase compared to the prior year, driven by both organic growth and significant acquisitions.
  • 2The company completed substantial acquisitions, including FEI Company for $4.08 billion and Affymetrix, Inc. for $1.34 billion, significantly boosting its Analytical Instruments and Life Sciences Solutions segments, respectively.
  • 3Net income for the quarter was $473.5 million, with diluted earnings per share of $1.19, showing stability despite integration costs.
  • 4Operating income was $541.1 million, with an operating margin of 12.0%, a slight decrease from the prior year's 13.7% due to higher restructuring and acquisition-related costs.
  • 5Cash flow from operations for the nine months ended October 1, 2016, was strong at $1.95 billion, indicating healthy cash generation capabilities.
  • 6The company's balance sheet reflects a significant increase in Goodwill and Acquisition-related Intangible Assets, totaling $21.58 billion and $14.52 billion respectively, due to recent acquisitions.
  • 7Thermo Fisher successfully managed its financing activities, raising $7.61 billion in debt issuance and increasing commercial paper to fund acquisitions, while repaying $2.31 billion in debt.

Frequently Asked Questions

Revenue growth was driven by a combination of organic growth, particularly in the pharmaceutical and biotech industries, and significant contributions from recent acquisitions, notably FEI Company and Affymetrix, Inc. The Life Sciences Solutions and Analytical Instruments segments showed particularly strong performance.

The company's aggressive acquisition strategy, including the large acquisitions of FEI Company and Affymetrix, Inc., significantly increased its total assets, particularly goodwill and intangible assets. These acquisitions boosted revenues but also led to higher restructuring and acquisition-related costs, which impacted operating income margins in the short term.

Thermo Fisher generated strong cash flow from operations, totaling $1.95 billion for the first nine months of 2016. The company also raised substantial debt and managed its financing activities effectively to fund its significant acquisition spending and meet its financial obligations. Its existing cash balance and future operating cash flow, along with available credit, are expected to be sufficient for its needs.

The company's balance sheet shows substantial long-term obligations, largely due to debt financing for acquisitions. Additionally, Note 10 details potential liabilities related to environmental matters and ongoing litigation, including intellectual property disputes and product liability claims. While the company has accrued for certain matters, it notes that unfavorable outcomes could potentially have a material adverse effect.